Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

Investigational New Drugs

Volumn 25, Issue 3, 2007, Pages 271-276

  Zhao, Liangli ^a   Marshall, Elaine S ^a   Kelland, Lloyd R ^b   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Endothelial; Matrigel; p38 kinase; Tubulogenesis; Vascular disrupting agents

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; AS 1404; GELATINASE A; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE P38; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ARTICLE; CELL FUNCTION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION PROFILING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MELANOMA CELL; MICROENVIRONMENT; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIMULATION; TISSUE CULTURE CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; LAMININ; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MICE, NUDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PROTEOGLYCANS; PYRIDINES; RNA, MESSENGER; XANTHONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34248653457     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-9029-0     Document Type: Article

References (21)

1. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nature Rev Cancer 5:423-435
2. Rewcastle GW, Atwell GJ, Li ZA, Baguley BC, Denny WA (1991) Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34:217-222
3. Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, Padhani AR (2002) Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20:3826-3840
4. Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC (2002) Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 86:1937-1942
5. Kestell P, Zhao L, Jameson MB, Stratford MR, Folkes LK, Baguley BC (2001) Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clin Chim Acta 314:159-166
6. Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, McCrystal MR, Small M, Bellenger K, Gumbrell L, Halbert GW, Kestell P (2003) Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 88:1844-1850
7. McKeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, Ravic M, Jameson MB (2006) 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 12:1776-1784
8. Rustin GJ, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, Bellenger K, Gumbrell L, Folkes L, Halbert G (2003) 5,6-dimethylxanthenone-4- acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 88:1160-1167
9. McKeage MJ, AS1404-201 Study Group Investigators (2006) Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). J Clin Oncol 24:7102
10. Parmar J, Marshall ES, Charters GA, Holdaway KM, Shelling AN, Baguley BC (2000) Radiation-induced cell cycle delays and p53 status of early passage melanoma cell lines. Oncol Res 12:149-155
11. Marshall ES, Holdaway KM, Shaw JH, Finlay GJ, Matthews JH, Baguley BC (1993) Anticancer drug sensitivity profiles of new and established melanoma cell lines. Oncol Res 5:301-309
12. Drinkwater SL, Smith A, Sawyer BM, Burnand KG (2002) Effect of venous ulcer exudates on angiogenesis in vitro. Br J Surg 89:709-713
13. Sengupta S, Sellers LA, Matheson HB, Fan TP (2003) Thymidine phosphorylase induces angiogenesis in vivo and in vitro: an evaluation of possible mechanisms. Br J Pharmacol 139:219-231
14. Rybak SM, Sanovich E, Hollingshead MG, Borgel SD, Newton DL, Melillo G, Kong D, Kaur G, Sausville EA (2003) "Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies. Cancer Res 63:2812-2819
15. Ching LM, Zwain S, Baguley BC (2004) Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 90:906-910
16. Zhao L, Ching LM, Kestell P, Kelland LR, Baguley BC (2005) Mechanisms of tumor vascular shut-down induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA); increased tumor vascular permeability. Int J Cancer 116:322-326
17. Ferrero E, Zocchi MR, Magni E, Panzeri MC, Curnis F, Rugarli C, Ferrero ME, Corti A (2001) Roles of tumor necrosis factor p55 and p75 receptors in TNF-alpha-induced vascular permeability. Am J Physiol - Cell Physiol 281:C1173-C1179
18. McMullen ME, Bryant PW, Glembotski CC, Vincent PA, Pumiglia KM (2005) Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. J Biol Chem 280:20995-21003
19. Hess AR, Seftor EA, Seftor RE, Hendrix MJ (2003) Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 63:4757-4762
20. Hendrix MJ, Seftor EA, Hess AR, Seftor RE (2003) Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nature Rev Cancer 3:411-421
21. Reisdorff J, En-Nia A, Stefanidis I, Floege J, Lovett DH, Mertens PR (2002) Transcription factor Ets-1 regulates gelatinase a gene expression in mesangial cells. J Am Soc Nephrol 13:1568-1578